PRO 140: Ph IIb/III started

CytoDyn began an open-label, U.S. Phase IIb/III trial to evaluate 350 mg subcutaneous PRO 140 once weekly as monotherapy for 48 weeks in about 300 patients with CCR5-tropic HIV-1 infection who are cli...